FOR IMMEDIATE RELEASE
“Beyond Shielding: The Roles of Glycans in SARS-CoV-2 Spike Protein”
ACS Central Science
As the COVID-19 pandemic rages on, researchers are working overtime to develop vaccines and therapies to thwart SARS-CoV-2, the virus responsible for the disease. Many efforts focus on the coronavirus spike protein, which binds the angiotensin-converting enzyme 2 (ACE2) on human cells to allow viral entry. Now, researchers reporting in ACS Central Science have uncovered an active role for glycans –– sugar molecules that can decorate proteins –– in this process, suggesting targets for vaccines and therapies.
Before the SARS-CoV-2 spike protein can interact with ACE2 on a human cell, it changes shape to expose its receptor binding domain (RBD), the part of the protein that interacts with ACE2. Like many viral proteins, the SARS-CoV-2 spike protein has a thick coat of glycans on its surface. These glycans, which are attached at specific sites, help shield the viral proteins from the host immune system. Rommie Amaro and colleagues at University of California San Diego, Maynooth University (Ireland) and the University of Texas at Austin wondered whether certain glycans in the SARS-CoV-2 spike protein might also be active players in the process leading to infection.
To find out, the researchers used structural and glycomic data to build molecular dynamics simulations of the SARS-CoV-2 spike protein embedded in the viral membrane. The computer models, which presented a detailed snapshot of every atom in the spike glycoprotein, revealed that N-glycans linked to the spike protein at certain sites (N165 and N234) helped stabilize the shape change that exposes the RBD, which could help promote infection. The simulations also identified regions of the spike protein that weren’t coated by glycans and thus could be vulnerable to antibodies, especially after the shape change. In laboratory experiments using biolayer interferometry, the team showed that mutating the spike protein so that it no longer had glycans at N165 and N234 reduced binding to ACE2. These results lay the foundation for new strategies to fight the pandemic, the researchers say.
The authors acknowledge funding from the National Institutes of Health, the National Science Foundation, the Research Corporation for Science Advancement, UC San Diego Moores Cancer Center, the Irish Research Council and the Visible Molecular Cell Consortium.
To automatically receive press releases from the American Chemical Society, contact firstname.lastname@example.org.
Note: ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies.
Note: ACS does not conduct research but publishes and publicizes peer-reviewed scientific studies.